12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hsp90 inhibitor: Interim Phase Ib/II data

Interim data from 22 evaluable HER2-positive, advanced breast cancer patients who failed 1-2 prior anti- HER2 regimens in the Phase II portion of an open-label, international Phase Ib/II trial showed that once-weekly 70 mg/m 2 IV AUY922 plus Herceptin trastuzumab produced 5 partial responses. Data from 11 patients in the Phase Ib...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >